Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751891 | 0.77 | HMOX1 (0.53) | CYP19A1TBXAS1 | |
| SCHEMBL2356874 | 0.73 | CYP17A1 (0.53) | CYP11B1CYP11B2CYP17A1CYP19A1TBXAS1 | |
| SCHEMBL4552528 | 0.73 | CASP1 (0.46) | HSD17B1 | |
| SCHEMBL4816440 | 0.73 | TBXAS1 (0.48) | CYP17A1CYP19A1TBXAS1KCNJ1KCNH2 | |
| SCHEMBL2353185 | 0.72 | CYP11B1 (0.43) | CYP11B1CYP11B2CYP17A1CYP19A1TBXAS1 | |
| SCHEMBL14495944 | 0.71 | GPR3 (0.46) | TBXAS1HSD17B1 | |
| SCHEMBL2015419 | 0.71 | GPR3 (0.46) | TBXAS1HSD17B1 | |
| SCHEMBL3238273 | 0.71 | CASP1 (0.47) | HSD17B1 | |
| SCHEMBL6752974 | 0.70 | HMOX1 (0.51) | CYP19A1TBXAS1 | |
| SCHEMBL2347295 | 0.70 | CYP17A1 (0.60) | CYP11B1CYP11B2CYP17A1CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | ARES TRADINS S.A. (CH) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171660-A1 | Single dose aromatase inhibitor for treating infertility | CYP19A1, FSHR, SHBG | CYP11B1 56/4885CYP11B2 99/4885CYP17A1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.